18F-ASIS

Gastric Carcinoma

Var2 PharmaceuticalsEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 89/ 100

Competitive context

36 Active assets in the Gastric Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan City of Hope Medical Center	Phase 1/2	CCC
Larotrectinib National Cancer Institute (NCI)	Phase 2	CCC
Binimetinib National Cancer Institute (NCI)	Phase 2	CCC
GSK-2636771 National Cancer Institute (NCI)	Phase 2	CCC
Fexagratinib National Cancer Institute (NCI)	Phase 2	CCC

View all 44 →

Same molecule, other indications

18F-ASIS is also rated in:

Inflammatory Demyelinating DiseaseDormant

CCC

Indicative ·

53 / 100

Thymus NeoplasmsDormant

CCC

Indicative ·

53 / 100

Non-small Cell Lung CancerDormant

CCC

Indicative ·

50 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.